Nov. 19, 2024 - VeriSIM Life today announced that its platform has once again been named "Predictive Analytics Solution of the Year" by the 2024 BioTech Breakthrough Awards. The company was first recognized in the same category in 2022, then again in 2023. The awards program is conducted by BioTech Breakthrough, a leading independent marketing intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
VeriSIM Life was recognized for its AtlasGEN Novel Drug Designer, which combines generative-AI chemical discovery with biological validation to dramatically compress drug candidate selection and reduce costly experimental research, while increasing the likelihood of clinical success. It efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
VeriSIM Life addresses the "translational gap" in drug development by guiding drug developers on where to focus experiments and investments. This innovation accelerates the drug development process, reducing costs and timelines to an unprecedented degree. BIOiSIM has enabled industry giants such as Mayo Clinic, Debiopharm, and Daiichi-Sankyo to advance drug candidates from early research to clinical trials significantly faster than traditional methods allow.
VeriSIM Life's portfolio includes six drug assets currently under development, led by PT001, a promising treatment for pulmonary arterial hypertension. Achieving pre-IND status in under three years, PT001 exemplifies the platform’s capability to expedite drug development—an industry milestone in a field where this phase typically takes six years or more. The BIOiSIM platform’s capabilities span therapeutic areas, including oncology, substance use disorders, and rare diseases, positioning VeriSIM Life as a pivotal partner in groundbreaking drug development.
“I am honored that VeriSIM Life continues to be recognized for its breakthrough technology and unprecedented potential to help drug developers bring their next successful treatment to market faster,” says CEO & Founder Dr. Jo Varshney.
The BioTech Breakthrough Awards program “aims to perform the most comprehensive evaluation of life sciences and biotechnology tools, services and companies today, with nominations coming in from the best and brightest biotechnology innovators around the world.”
About VeriSIM Life
VeriSIM Life has developed BIOiSIM®, an advanced computational platform that harnesses AI and machine learning to transform drug discovery and development. As a first-in-class virtual drug development engine, BIOiSIM delivers exceptional value to the industry by quickly identifying drug candidates with the highest potential for treating or curing specific diseases. The platform predicts clinical trial success rates early in the preclinical stage, enabling developers to focus on the most viable options. By reducing unnecessary experiments and guiding critical program decisions, BIOiSIM significantly cuts down on time and cost, accelerating the path from discovery to market for life-saving therapies. For more information, visit www.verisimlife.com.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
